I only got a chance to review this now, good to see under 2025 milestones they have "commence phase 3 trial for PMS"
forgetting about a TO and the share price for a moment, it's good to see we are continuing to push forward which will inevitably increase the value of the broader asset (acknowledging we are still waiting to hear the outcome from the FDA meeting re endpoints)
Ann: Neuren JP Morgan Healthcare Conference 2025 presentation, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |